SignatureFD’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

SignatureFD’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-87	Closed	-$274	–	3329
2023 Q2	$274	Hold	87	–	–	﹤0.01%	3113
2023 Q1	$232	Hold	87	–	–	﹤0.01%	3178
2022 Q4	$312	Hold	87	–	–	﹤0.01%	3154
2022 Q3	$1K	Buy	+87	New	+$707	﹤0.01%	3060
2021 Q4	–	Sell	-20	Closed	-$1K	–	3299
2021 Q3	$1K	Buy	20 +3	+18%	+$146	﹤0.01%	2958
2021 Q2	$1K	Buy	+17	New	+$1.01K	﹤0.01%	2872

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

SignatureFD's SYRS Position: Q3 2023 in Review

SignatureFD sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2023, closing a stake of 87 shares — an estimated $274 sold.

SignatureFD first reported a position in SYRS in Q2 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 48 funds tracked by Wall St. Rank hold SYRS as of Q3 2023.

SignatureFD reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
SignatureFD sold 87 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $274.
SignatureFD first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
SignatureFD's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q3 2022.
48 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on SignatureFD's 13F filing for Q3 2023, filed 3 Nov 2023.